Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cyprotex Acquires CeeTox

Published: Thursday, January 02, 2014
Last Updated: Thursday, January 02, 2014
Bookmark and Share
Auquistion broadens toxicological assay and screening capabilities to the cosmetic and personal care industry.

Cyprotex PLC announces the acquisition of the business and assets of CeeTox, Inc, a division of North American Science Associates, Inc.

CeeTox, based in Kalamazoo, MI, USA, is a Contract Research Organisation specialising in the provision of in vitro toxicological assays and screening data, principally to the Cosmetic and Personal Care Industries. Founded in 2003, CeeTox was acquired in 2005 by NAMSA, a medical research organisation supplying expert consulting, clinical and laboratory services to medical device, IVD and biologics manufacturers. NAMSA retains a license for applying CeeTox’s in vitro toxicology expertise to medical device testing. CeeTox had sales of approximately £2.3 million in the year ended 30 September 2013 and made an operating loss of approximately £0.9 million. The initial consideration for the purchase of £0.63 million is funded by internal cash resources, with a further consideration of 5% payable on specified net sales achieved in the next four years to a maximum of £3.1 million. The purchase is made by the group’s US trading subsidiary, Apredica, LLC. The impact of the acquisition is expected to be earnings neutral in the first year.

It is expected that Cyprotex will continue to operate the CeeTox business from its Kalamazoo location for a period of time prior to relocation of the business and assets to Cyprotex’s US base in Watertown, MA.

Commenting on the acquisition, Dr Anthony Baxter, CEO of Cyprotex, said: “The acquisition of CeeTox and its world-respected in vitro toxicology assays affords Cyprotex the opportunity to grow revenues significantly. Principally, it enables the Company to offer a more complete assay and screening service to the Cosmetics and Personal Care Industry, already an expanding customer segment, and will materially extend the Company’s footprint in its established core Pharmaceutical and Agrochemical industry markets.

“The innovative assays and screens that CeeTox has developed over its 10-year life are complementary to our existing comprehensive platform. In particular, we are excited by the potential for selling the Endocrine Disruptor Screening Programme (EDSP) service to both current Government agency customers and to industrial chemical companies.”

Mr. Tim Mitchell, CEO of CeeTox, added: “We are delighted that, in acquiring the CeeTox business, Cyprotex is committed to both maintaining our reputation for innovative high quality science and to growing our existing customer base. The combination of our two businesses represents an outstanding opportunity to leverage our capabilities and capitalise on the enormous market potential across a variety of industries that require in vitro toxicity screening services.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cyprotex Appoints Dr Rob Elsby as Leader of Drug Transporter Team
Cyprotex PLC has appointed Dr Rob Elsby as Leader of its Drug Transporter Team.
Wednesday, March 18, 2015
Cyprotex Announces a Collaborative Research Agreement with Pfizer
The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved.
Friday, November 02, 2012
Cyprotex Launch Updated Drug-Drug Interaction Regulatory Guidance
Booklet to reflect the new FDA and EMA guidelines.
Friday, August 17, 2012
Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance
The companies have announced they have entered into an extension of their highly successful partnership for a further 2 years.
Monday, December 19, 2011
Cyprotex Extends Cloe® Screen Mechanism-Based Inhibition Service to Include 4 Additional Cytochrome P450 Isoforms
New assays compliment the CYP3A4 isoform assay which was launched last year.
Friday, March 30, 2007
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos